Biologic Switching in PsA: 5 Things Rheumatologists Need to Know

In this slideshow, we highlight five of the top concerns and questions physicians have about switching patients from one biologic to another in psoriatic arthritis.

References:

Yamauchi PS, et al. “Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent.” Journal of the American Academy of Dermatology Volume 75, Issue 3, September 2016, Pages 612–618.

Doshi J, et al. “Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.”  Journal of the American Academy of Dermatology Volume 74, Issue 6, June 2016 Pages 1057–1065.

Kristensen LE, et al. “Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.” The Journal of Rheumatology Published online before print December 1, 2015, doi: 10.3899/jrheum.150744

Abramson SR, et al. “A Review of Current Evidence for TNF Inhibitor Switching in Psoriatic Arthritis.” Journal of Psoriasis and Psoriatic Medicine, Volume 1, Number 3.

Calara PS, et al.  “Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.” BioDrugs (2016) 30: 145. doi:10.1007/s40259-016-0163-8

Zhou Z, et al. “Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.” Zhou, Z., Griffith, J., Du, E.X. et al. Adv Ther (2016) 33: 807. doi:10.1007/s12325-016-0318-5

Cannon GW, et al. “Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.” Adv Ther (2016) 33: 1347. doi:10.1007/s12325-016-0371-0